Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2015', provides an overview of the Lixte Biotechnology Holdings, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lixte Biotechnology Holdings, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lixte Biotechnology Holdings, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lixte Biotechnology Holdings, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lixte Biotechnology Holdings, Inc.'s pipeline products

Reasons to buy

- Evaluate Lixte Biotechnology Holdings, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lixte Biotechnology Holdings, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lixte Biotechnology Holdings, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lixte Biotechnology Holdings, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lixte Biotechnology Holdings, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Lixte Biotechnology Holdings, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Lixte Biotechnology Holdings, Inc. Snapshot 5
Lixte Biotechnology Holdings, Inc. Overview 5
Key Information 5
Key Facts 5
Lixte Biotechnology Holdings, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Lixte Biotechnology Holdings, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Lixte Biotechnology Holdings, Inc. - Pipeline Products Glance 11
Lixte Biotechnology Holdings, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Lixte Biotechnology Holdings, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Lixte Biotechnology Holdings, Inc. - Drug Profiles 13
LB-100 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
LB-102 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
LB-201 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
LB-205 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
LB-300 Series 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
LB-400 Series 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Lixte Biotechnology Holdings, Inc. - Pipeline Analysis 20
Lixte Biotechnology Holdings, Inc. - Pipeline Products by Target 20
Lixte Biotechnology Holdings, Inc. - Pipeline Products by Route of Administration 21
Lixte Biotechnology Holdings, Inc. - Pipeline Products by Molecule Type 22
Lixte Biotechnology Holdings, Inc. - Pipeline Products by Mechanism of Action 23
Lixte Biotechnology Holdings, Inc. - Recent Pipeline Updates 24
Lixte Biotechnology Holdings, Inc. - Dormant Projects 26
Lixte Biotechnology Holdings, Inc. - Company Statement 27
Lixte Biotechnology Holdings, Inc. - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables

Lixte Biotechnology Holdings, Inc., Key Information 5
Lixte Biotechnology Holdings, Inc., Key Facts 5
Lixte Biotechnology Holdings, Inc. - Pipeline by Indication, 2015 7
Lixte Biotechnology Holdings, Inc. - Pipeline by Stage of Development, 2015 9
Lixte Biotechnology Holdings, Inc. - Monotherapy Products in Pipeline, 2015 10
Lixte Biotechnology Holdings, Inc. - Phase I, 2015 11
Lixte Biotechnology Holdings, Inc. - Preclinical, 2015 12
Lixte Biotechnology Holdings, Inc. - Pipeline by Target, 2015 20
Lixte Biotechnology Holdings, Inc. - Pipeline by Route of Administration, 2015 21
Lixte Biotechnology Holdings, Inc. - Pipeline by Molecule Type, 2015 22
Lixte Biotechnology Holdings, Inc. - Pipeline Products by Mechanism of Action, 2015 23
Lixte Biotechnology Holdings, Inc. - Recent Pipeline Updates, 2015 24
Lixte Biotechnology Holdings, Inc. - Dormant Developmental Projects,2015 26